Efficacy and tolerability of diphenyl-dimethyldicarboxylate plus garlic oil in patients with chronic hepatitis

International Journal of Clinical Pharmacology and Therapeutics

Volumn 50, Issue 11, 2012, Pages 778-786

  Lee, Min Ho ^a   Kim, Young Mi ^b   Kim, Sang Geon ^b  

^a Hanyang University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

ALT; AST; Chronic hepatitis; DDB; Garlic oil; HBV; HCV

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DICARBOXYLIC ACID DERIVATIVE; DIMETHYL 4,4' DIMETHOXY 5,6,5',6' DIMETHYLENE DIOXYBIPHENYL 2,2' DICARBOXYLATE; GARLIC OIL; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC HEPATITIS; CONTROLLED STUDY; DISEASE MARKER; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; EVENING DOSAGE; FEMALE; HISTOPATHOLOGY; HUMAN; KOREA; LABORATORY TEST; LIVER INJURY; LIVER PROTECTION; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE;

ADMINISTRATION, ORAL; ADULT; AGED; ALANINE TRANSAMINASE; ALLYL COMPOUNDS; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; CAPSULES; DIOXOLES; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER; MALE; MIDDLE AGED; PROTECTIVE AGENTS; REPUBLIC OF KOREA; SULFIDES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84867914743     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201746     Document Type: Article

References (46)

1. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994; 19: 1513-1520.doi:10.1002/hep.1840190629 PubMed (Pubitemid 24166476)
2. Hoofnagle JH, di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med. 1997; 336: 347-356.doi:10.1056/NEJM199701303360507 PubMed
3. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004; 11: 97-107. doi:10.1046/j.1365-2893.2003.00487.x PubMed (Pubitemid 38365759)
4. Alter MJ, Mast EE. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am. 1994; 23: 437-455. PubMed (Pubitemid 24283692)
5. Xie JX, Zhou J, Zhang CZ, Yang JH, Jin HQ, Chen JX. [Synthesis of schizandrin C analogs. II. Synthesis of dimethyl-4, 4′-dimethoxy-5, 6, 5′, 6′- di-methylenedioxybiphenyl- 2, 2′-dicarboxylate and its isomers (author's transl)]. Yao Xue Xue Bao. 1982; 17: 23-27. PubMed
6. El-Bahy AA, Kassem LA, Heikal OA, Mahran LG. Antiapoptotic effect of DDB against hepatic ischemia-reperfusion injury. J Toxicol Sci. 2011; 36: 145-154.doi:10.2131/jts.36.145 PubMed
7. Abdel-Salam OM, Sleem AA, Morsy FA. Effects of biphenyldimethyl- dicarboxylate administration alone or combined with silymarin in the CCL4 model of liver fibrosis in rats. ScientificWorld-Journal. 2007; 7: 1242-1255.doi:10.1100/tsw.2007.193 PubMed (Pubitemid 47327826)
8. Zhang YX, Yu HQ, Shi JZ, Qi HB, Dong ZH, Xu HY. The therapeutic effect of biphenyl-dimethyldicarboxylate (DDB) on certain abnormal laboratory parameters in chronic hepatitis. J Tradit Chin Med. 1987; 7: 137-138. PubMed
9. Cui S, Wang M, Fan G. [Anti-HBV efficacy of bifendate in treatment of chronic hepatitis B, a primary study]. Zhonghua Yi Xue Za Zhi (Taipei). 2002; 82: 538-540. PubMed
10. Akbar N, Tahir RA, Santoso WD, Soemarno, Sumaryono, Noer HM, Liu G. Effectiveness of the analogue of natural Schisandrin C (HpPro) in treatment of liver diseases: an experience in Indonesian patients. Chin Med J (Engl). 1998; 111: 248-251. PubMed
11. Lee HS, Kim YT, Jung HC, Yoon YB, Song IS, Kim CY. Prospective randomized controlled trial with diphenyldimethyldicarboxylate in chronic active liver disease: the effect on lowering serum alanine aminotransferase levels. Korean J Intern Med. 1991; 40: 173-178.
12. Kim SG, Kim HJ, Choi SH, Ryu JY. Inhibition of lipopolysaccharide-induced I-kappaB degradation and tumor necrosis factor-alpha expression by dimethyl-4,4′-dimethoxy-5,6,5′,6′-dimethylene dioxybiphenyl-2,2′-dicarboxylate (DDB): minor role in hepatic detoxifying enzyme expression. Liver. 2000; 20: 319-329. doi:10.1034/j.1600-0676.2000. 020004319.x PubMed (Pubitemid 30496570)
13. Huber R, Hockenjos B, Blum HE. DDB treatment of patients with chronic hepatitis. Hepatology. 2004; 39: 1732-1733.doi:10.1002/hep.20247 PubMed (Pubitemid 38702675)
14. Kim SG, Nam SY, Chung HC, Hong SY, Jung KH. Enhanced effectiveness of dimethyl-4,4′-dimethoxy-5,6,5′,6′-dimethylene dioxybiphenyl- 2,2′-dicarboxylate in combination with garlic oil against experimental hepatic injury in rats and mice. J Pharm Pharmacol. 1995; 47: 678-682. doi:10.1111/j.2042-7158.1995.tb05859.x PubMed
15. Kim SG, Chung HC, Cho JY. Molecular mechanism for alkyl sulfide-modulated carbon tetrachloride-induced hepatotoxicity: the role of cytochrome P450 2E1, P450 2B and glutathione S-transferase expression. J Pharmacol Exp Ther. 1996; 277: 1058-1066. PubMed (Pubitemid 127613412)
16. Wu CC, Sheen LY, Chen HW, Tsai SJ, Lii CK. Effects of organosulfur compounds from garlic oil on the antioxidation system in rat liver and red blood cells. Food Chem Toxicol. 2001; 39: 563-569. doi:10.1016/S0278-6915(00)00171-X PubMed (Pubitemid 32429469)
17. Sparnins VL, Barany G, Wattenberg LW. Effects of organosulfur compounds from garlic and onions on benzo[a]pyrene-induced neoplasia and glutathione S-transferase activity in the mouse. Carcinogenesis. 1988; 9: 131-134.doi:10.1093/carcin/9.1.131 PubMed
18. Brady JF, Ishizaki H, Fukuto JM, Lin MC, Fadel A, Gapac JM, Yang CS. Inhibition of cytochrome P-450 2E1 by diallyl sulfide and its metabolites. Chem Res Toxicol. 1991; 4: 642-647.doi:10.1021/tx00024a008 PubMed
19. Kwak MK, Kim SG, Kwak JY, Novak RF, Kim ND. Inhibition of cytochrome P4502E1 expression by organosulfur compounds allylsulfide, allylmercaptan and allylmethylsulfide in rats. Biochem Pharmacol. 1994; 47: 531-539.doi:10.1016/ 0006-2952(94)90185-6 PubMed (Pubitemid 24071534)
20. Park EY, Ki SH, Ko MS, Kim CW, Lee MH, Lee YS, Kim SG. Garlic oil and DDB, comprised in a pharmaceutical composition for the treatment of patients with viral hepatitis, prevents acute liver injuries potentiated by glutathione deficiency in rats. Chem Biol Interact. 2005; 155: 82-96. doi:10.1016/j.cbi. 2005.04.006 PubMed
21. World Health Organization. Hepatitis B. (Fact sheet No. 204). Geneva, Switzerland: WHO, 2008. (http://www.who.int/mediacentre/factsheets/fs204/en/ index. html).
22. World Health Organization. Hepatitis C. (Fact sheet No. 164). Geneva, Switzerland: WHO, 2011. (http://www.who.int/mediacentre/factsheets/fs164/en/ index. html).
23. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006; 45: 529-538.doi:10.1016/j. jhep.2006.05.013 PubMed (Pubitemid 44307383)
24. Pawlotsky JM. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology. 2011; 53: 1742-1751. doi:10.1002/hep.24262 PubMed
25. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology. 1997; 26 (Suppl 1): 112S-121S.doi:10.1002/hep.510260720 PubMed (Pubitemid 27388083)
26. Xu XW, Chen YG. Current therapy with nucleoside/nucleotide analogs for patients with chronic hepatitis B. Hepatobiliary Pancreat Dis Int. 2006; 5: 350-359. PubMed
27. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD, Chien RN; Asia Hepatitis Lamivudine Study Group. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology. 2001; 33: 1527-1532.doi:10.1053/jhep.2001.25084 PubMed (Pubitemid 32496991)
28. Honkoop P, de Man RA, Heijtink RA, Schalm SW. Hepatitis B reactivation after lamivudine. Lancet. 1995; 346: 1156-1157.doi:10.1016/S0140-6736(95)91829-9 PubMed
29. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD; Lamivudine Clinical Investigation Group. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology. 1998; 27: 1670-1677.doi:10.1002/hep.510270628 PubMed (Pubitemid 28264693)
30. Loguercio C, Federico A. Oxidative stress in viral and alcoholic hepatitis. Free Radic Biol Med. 2003; 34: 1-10.doi:10.1016/S0891- 5849(02)01167-X PubMed
31. Shimoda R, Nagashima M, Sakamoto M, Yamaguchi N, Hirohashi S, Yokota J, Kasai H. Increased formation of oxidative DNA damage, 8-hydroxydeoxyguanosine, in human livers with chronic hepatitis. Cancer Res. 1994; 54: 3171-3172. PubMed (Pubitemid 24208923)
32. Mahmood S, Kawanaka M, Kamei A, Izumi A, Nakata K, Niiyama G, Ikeda H, Hanano S, Suehiro M, Togawa K, Yamada G. Immunohistochemical evaluation of oxidative stress markers in chronic hepatitis C. Antioxid Redox Signal. 2004; 6: 19-24. doi:10.1089/152308604771978318 PubMed (Pubitemid 38063973)
33. Parola M, Robino G. Oxidative stress-related molecules and liver fibrosis. J Hepatol. 2001; 35: 297-306.doi:10.1016/S0168-8278(01)00142-8 PubMed (Pubitemid 32803489)
34. Choi J, Ou JH. Mechanisms of liver injury. III. Oxidative stress in the pathogenesis of hepatitis C virus. Am J Physiol Gastrointest Liver Physiol. 2006; 290: G847-G851. PubMed
35. Agarwal KC. Therapeutic actions of garlic constituents. Med Res Rev. 1996; 16: 111-124. doi: 10.1002/(SICI)1098-1128(199601)16:1 〈111::AID- MED4〉3.0.CO;2-5 PubMed
36. Bordia A, Verma SK. Effect of garlic feeding on regression of experimental atherosclerosis in rabbits. Artery. 1980; 7: 428-437. PubMed (Pubitemid 11145800)
37. Ashraf BA, Amani EK, Sherif HA. Protective effects of garlic oil against liver damage induced by combined administration of ethanol and carbon tetrachloride in rats. Egyp J Hosp Med. 2002; 6: 27-36.
38. Bordia A, Bansal HC, Arora SK, Singh SV. Effect of the essential oils of garlic and onion on alimentary hyperlipemia. Atherosclerosis. 1975; 21: 15-19. doi:10.1016/0021-9150(75)90091-X PubMed
39. Kwon SY, Lee CH. Epidemiology and prevention of hepatitis B virus infection. Korean J Hepatol. 2011; 17: 87-95.doi:10.3350/kjhep.2011.17.2.87 PubMed
40. Friedman LS, Martin P and Munoz SJ. Liver function tests and the objective evaluation of the patients with liver disease. In: Zakim D and Boyer TD (eds). Hepatology. A textbook of liver disease 3rd WB Saunders; Philadelphia, London, Toronto 1996; 28: 791-810.
41. Rej R. Aspartate aminotransferase activity and isoenzyme proportions in human liver tissues. Clin Chem. 1978; 24: 1971-1979. PubMed (Pubitemid 9049072)
42. Kim HS, Lee ST, Kim DG, Ahn DS. A study on the efficacy and safety of dipheny-dimethyl-dicarboxylate in patients with chronic liver disease. Korean J Hepatol. 1996; 2: 54-60.
43. Harris JC, Cottrell SL, Plummer S, Lloyd D. Antimicrobial properties of Allium sativum (garlic). Appl Microbiol Biotechnol. 2001; 57: 282-286. doi:10.1007/s002530100722 PubMed (Pubitemid 32972334)
44. O'Gara EA, Hill DJ, Maslin DJ. Activities of garlic oil, garlic powder, and their diallyl constituents against Helicobacter pylori. Appl Environ Microbiol. 2000; 66: 2269-2273.doi:10.1128/AEM.66.5.2269-2273.2000 PubMed (Pubitemid 30253767)
45. Weber ND, Andersen DO, North JA, Murray BK, Lawson LD, Hughes BG. In vitro virucidal effects of Allium sativum (garlic) extract and compounds. Planta Med. 1992; 58: 417-423. doi:10.1055/s-2006-961504 PubMed
46. Shoji S, Furuishi K, Yanase R, Miyazaka T, Kino M. Allyl compounds selectively killed human immunodeficiency virus (type 1)-infected cells. Biochem Biophys Res Commun. 1993; 194: 610-621. doi:10.1006/bbrc.1993.1865 PubMed (Pubitemid 23245179)